These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9365714)

  • 1. [Role and value of oxaliplatin in metastatic colorectal cancers].
    Louvet C; de Gramont A
    Rev Med Interne; 1997; 18 Suppl 4():368s-371s. PubMed ID: 9365714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin: a review of its use in the management of metastatic colorectal cancer.
    Wiseman LR; Adkins JC; Plosker GL; Goa KL
    Drugs Aging; 1999 Jun; 14(6):459-75. PubMed ID: 10408744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer.
    Simpson D; Dunn C; Curran M; Goa KL
    Drugs; 2003; 63(19):2127-56. PubMed ID: 12962525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin: a review of preclinical and clinical studies.
    Raymond E; Chaney SG; Taamma A; Cvitkovic E
    Ann Oncol; 1998 Oct; 9(10):1053-71. PubMed ID: 9834817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA drug approval summaries: oxaliplatin.
    Ibrahim A; Hirschfeld S; Cohen MH; Griebel DJ; Williams GA; Pazdur R
    Oncologist; 2004; 9(1):8-12. PubMed ID: 14755010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin (L-OHP): a new reality in colorectal cancer.
    Bleiberg H
    Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):1-3. PubMed ID: 9647611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer.
    Becouarn Y; Rougier P
    Semin Oncol; 1998 Apr; 25(2 Suppl 5):23-31. PubMed ID: 9609105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
    Culy CR; Clemett D; Wiseman LR
    Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin in practice.
    Misset JL
    Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):4-7. PubMed ID: 9647612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Oxaliplatin: the first DACH platinum in clinical practice].
    Soulié P; Raymond E; Brienza S; Cvitkovic E
    Bull Cancer; 1997 Jun; 84(6):665-73. PubMed ID: 9295871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating oxaliplatin into the management of colorectal cancer.
    Schmoll HJ; Cassidy J
    Oncologist; 2001; 6 Suppl 4():24-8. PubMed ID: 11585971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of oxaliplatin in colorectal cancer.
    O'Dwyer PJ; Johnson SW
    Semin Oncol; 2003 Jun; 30(3 Suppl 6):78-87. PubMed ID: 12802798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phase II clinical trial of oxaliplatin alone for refractory advanced colorectal cancer].
    Xu RH; Guan ZZ; Feng FY; He XH; Liu SJ; Di LJ; Li SF; Li LQ
    Ai Zheng; 2003 Aug; 22(8):874-6. PubMed ID: 12917039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
    Grivicich I; Mans DR; Peters GJ; Schwartsmann G
    Braz J Med Biol Res; 2001 Sep; 34(9):1087-103. PubMed ID: 11514832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study.
    Díaz-Rubio E; Sastre J; Zaniboni A; Labianca R; Cortés-Funes H; de Braud F; Boni C; Benavides M; Dallavalle G; Homerin M
    Ann Oncol; 1998 Jan; 9(1):105-8. PubMed ID: 9541691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
    Folprecht G; Köhne CH
    Nat Clin Pract Oncol; 2005 Nov; 2(11):578-87. PubMed ID: 16270098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oxaliplatin: a first DACH-platinum in oncology].
    Laadem A; Cvitkovic E
    Bull Cancer; 2001 Aug; 88 Spec No():S9-13. PubMed ID: 11567908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of oxaliplatin and its clinical use in colorectal cancer.
    Grothey A; Goldberg RM
    Expert Opin Pharmacother; 2004 Oct; 5(10):2159-70. PubMed ID: 15461551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.